ASH 2020 | Addition of daratumumab to R/R myeloma regimens improves outcomes
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, shares results from an analysis of measurable residual disease (MRD) negativity in relapsed/refractory (R/R) multiple myeloma patients treated in the Phase III CANDOR study (NCT03158688). Over 400 patients were randomized to receive carfilzomib (K), dexamethasone (d) and daratumumab (D), or Kd. KdD was established as superior with regards to progression-free survival (PFS). MRD negativity was established using next generation sequencing of bone marrow aspirates at 12 months. In patients achieving complete remission (CR), MRD-negativity rate at 12 months was 12.5% vs 1.3% in the KdD vs Kd arm. For all patients, results were 17.6% vs 3.9% in KdD and Kd, respectively. MRD responses were also deeper in the KdD arm. The findings support previous evidence of KdD’s efficacy in R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
